Approval · Notice of Compliance 2609 · 2001
VISUDYNE: Notice of Compliance 2609
Issued July 25, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2609
- Date
- July 25, 2001
- Company
- Qlt Inc.Vancouver, BC, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- Extension of the indication: to include the treatment of pathologic myopia in patients with predominantly classic subfoveal choroidal neovascularization (cnv)
- Therapeutic class
- Photosensitizing agent for age-related macular degeneration and pathologic myopia
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VISUDYNE | Not yet assigned | — |
Medicinal ingredients
- VERTEPORFIN 15 MG per VIAL